Olema Pharma Q2 net loss widens to $43.8 mln
Overview
Olema Q2 net loss widens to $43.8 mln from $30.4 mln last year
Cash and marketable securities total $361.9 mln, down from $434.1 mln last year
Co to report OPERA-01 top-line data in H2 2026, OPERA-02 to start Q3 2025
Q2 with $361.9 mlEnded n in cash, supporting ongoing and future clinical development activities
Outlook
Company expects OPERA-01 top-line data in H2 2026
Olema to initiate OPERA-02 trial in Q3 2025
Company plans to present Phase 1b/2 data at ESMO 2025
Initial clinical results for OP-3136 expected in 2026
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| -$43.78 mln |
|
Q2 Basic EPS |
| -$0.51 |
|
Q2 Income From Operations |
| -$47.86 mln |
|
Q2 Operating Expenses |
| $47.86 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $24.50, about 81.1% above its August 8 closing price of $4.64
Press Release: ID:nGNX1nt87y
